tbuckley/cabot-search huggingface dataset:
EARLY CORONARY ENDOTHELIAL DYSFUNCTION PREDICTS ACCELERATED PLAQUE PROGRESSION 1 YEAR AFTER CARDIAC TRANSPLANTATION: SERIAL VOLUMETRIC EVALUATION BY INTRAVASCULAR ULTRASOUND
Authors: Jang Hoon Lee, Kozo Okada, Kiran Khush, Yuhei Kobayashi, Seema Sinha, Helen Luikart, Hannah Valantine, Alan Yeung, Yasuhiro Honda, William Fearon
Journal: Journal of the American College of Cardiology (2016)
Elevated 99mTc 3PRGD2 Activity in Benign Metastasizing Leiomyoma
Authors: Xiaona Jin, Yunxiao Meng, Zhaohui Zhu, Hongli Jing, Fang Li
Journal: Clinical Nuclear Medicine (2013)

PET/CT scan was performed in a 43-year-old woman to evaluate pulmonary nodules/masses. The images showed that there was only minimal FDG activity in the masses. However, these soft tissue masses in the lungs had significantly elevated (99m)Tc 3PRGD(2) activity. Pathological examination demonstrated that this patient suffered benign metastasizing leiomyoma.
BONE MINERAL DENSITY AND SUBSEQUENT DEVELOPMENT OF HEART FAILURE IN OLDER ADULTS: THE CARDIOVASCULAR HEALTH STUDY
Authors: Raymond Fohtung, David Brown, William J.H. Koh, Traci Bartz, Laura Carbone, Roberto Civitelli, Phyllis Stein, Paulo Chaves, Bryan Kestenbaum, Jorge Kizer
Journal: Journal of the American College of Cardiology (2016)
Flashing, Pulsating Angioma
Authors: Christos C Zouboulis, Aikaterini I Liakou
Journal: New England Journal of Medicine (2012)

A 68-year-old man was admitted with eosinophilic pustular folliculitis of Ofuji, a pruritic eruption caused by eosinophilic infiltration of the hair follicles. While he was an inpatient, a single, round nodule developed overnight on his right thigh.
A 6 gene molecular predictor of lapatinib related benefit: from cell line models to clinical trials.
Authors: J Gray, D Das, P Spellman, N Wang, W Kuo, A Wyrobek, S Bhattacharya, M Press, A Di Leo, C Ellis, M Arbushites, M Casey, R Gagnon, M Koehler
Journal: Cancer Research (2009)

Abstract Abstract #58 Background: Identification of molecular predictors of response is an important aspect of individualized cancer treatment. Responses to lapatinib (L), an oral inhibitor of HER2 and EGFR, approved in combination with capecitabine for HER2+ metastatic breast cancer (MBC), were evaluated in a panel of BC cell lines. Computational approaches were used to identify transcripts that quantitatively associate with response to L in the cell line panel that were then tested in 2 clinical trials.&amp;#x2028; Methods: The clinical utility of a 6-gene predictor was tested retrospectively using a branched-chain DNA assay in paraffin-embedded archival tumor tissue from patients (pts) with HER2 negative or untested MBC tumors enrolled in a phase III trial of paclitaxel (P) vs. P+L, and from pts with HER2 positive MBC enrolled in a L monotherapy trial. Expression of HER2 transcript using the branched-chain assay was compared with HER2 fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) status; discordant cases were analyzed. Response patterns for pts with HER2+ tumors and a computational model that predicts L sensitivity or resistance is described.&amp;#x2028; Results: Ingenuity analysis of the mRNA predictors of response to L identified in the BC cell line panel revealed saturated gene networks with HER2 as a major node. The 6-gene predictor of response was comprised of 2 genes associated with sensitivity to L: HER2 and GRB7; 4 genes associated with resistance to L: CRK, ACOT9, FLJ31079, and DDX5. Expression results for the 6 genes and progression-free survival (PFS) data were available for 159 pts on L+P. Median PFS in the branched-chain HER2+ group was 32.9 wks vs. 22.4 wks in the HER2-negative group. The 6-gene predictor was used to predict response to L in the HER2+ pts. Comparison of PFS in the 24 “L sensitive” tumors vs. 25 “L resistant” tumors indicated that the predictor, derived from cell-line analyses, had the potential to predict clinical response to L in pts treated with L+P (HR=0.58; 95% CI=0.30-1.11; p=0.07). The 6-gene predictor was further tested in an independent L monotherapy study in pts with HER2 FISH+ MBC. Comparison of PFS in the 24 “L sensitive” tumors vs. 28 “ L resistant” tumors reconfirmed the potential of the 6-gene predictor to enrich for HER2+ pts most likely to experience clinical benefit from L (HR=0.40; 95% CI=0.19-0.84; p=0.015). Further testing is ongoing.&amp;#x2028; Conclusions: This study suggests that molecular predictors of clinical response can be developed through an analysis of response from a collection of 50 BC cell lines. The identification of a L specific 6-gene assay is promising as a clinical predictor of benefit from L in pts with HER2+ BC. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 58.
Sudden Deafness Associated with Adenovirus Infection
Authors: Burton F. Jaffe, Hunein F. Maassab
Journal: New England Journal of Medicine (1967)

SUDDEN unilateral deafness may be the presenting symptom of a wide variety of medical and surgical diseases, such as vascular occlusion, hypercoagulation, acoustic neuroma, ototoxic drugs, meningitis, syphilis, multiple sclerosis, collagen diseases, measles and mumps. The hearing loss may be partial or total and is frequently permanent when untreated. However, emergency treatment soon after the onset of the sudden deafness will restore the hearing to normal in over 60 per cent of the patients.1 , 2 This report documents the first patient with sudden deafness who was proved to have a viral infection. Adenovirus Type 3 was isolated from the nasopharynx and . . .
P5-20-08: Multicenter Results of Scalp Cooling To Prevent Chemotherapy-Induced Alopecia in 1500 Breast Cancer Patients.
Authors: den Hurk C van, M Peerbooms, M Komen, H Nortier, W Breed
Journal: Cancer Research (2011)

Abstract Background Chemotherapy-induced alopecia (CIA) is a frequent occurring side effect of cancer treatment that has high psychological impact on many patients and their relatives. CIA may be prevented by scalp cooling. Methods Breast cancer patients who received scalp cooling could participate in this registration study from 2006 and onwards. Nurses and patients completed questionnaires. Scalp cooling was performed using the Paxman PSC1 or PSC2 system and was considered satisfying when patients did not wear a wig or head cover. Logistic regression analyses will be used to examine determinants of the scalp cooling result, including age, type/length/thickness/chemical manipulation (dyeing, waving, colouring) of hair, type/dose of chemotherapy, cytostatic infusion time, post-infusion cooling time, dampening hair or use of conditioner before scalp cooling and previous treatment with chemotherapy. Results The use of scalp cooling increased from 4 hospitals in 2005 to 60 out of 100 Dutch hospitals in 2011. The registration comprised about 1500 scalp cooled breast cancer patients of whom 79% were treated in the adjuvant setting. Overall, patients’ satisfaction with the result of scalp cooling was 50%, but varied for different chemotherapy schemes and dosages from 8% in docetaxel 75 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 (TAC) to 81% in paclitaxel 70–90 mg/m2. The results of the regression analyses will be presented at the conference. Discussion Scalp cooling is effective in most commonly used chemotherapy regimens for breast cancer patients. Therefore, scalp cooling should be offered more often. Efficacy depends on the type and dose of chemotherapy. Other factors influencing the result have never been studied in multivariate analyses before. Scalp cooling is ineffective in patients treated with a combination of a taxane and an anthracyclin. The frequent use of scalp cooling in the adjuvant setting indicates minimal fear for an increased incidence of scalp skin metastases after scalp cooling in breast cancer patients. Multicenter registration of results improves information for medical professionals and patients and will lead to more frequent use of scalp cooling and improvement of the method. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-20-08.
AB1120 Rehabilitation of Temporomandibular Joint (TMJ) in Patients with Systemic Sclerosis (SSC). A Comparison between Two Protocols: Preliminary Results:
Authors: S. Maddali Bongi, A. Del Rosso, M. Passalacqua, G. Landi, C. Defraia, M. Matucci Cerinic
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> In SSc patients, microstomia is frequent and impairs mouth function. It may be due to fibrosis of skin face and to changes in TMJ, scarcely evaluated and treated with rehabilitation in SSc. <h3>Objectives</h3> To evaluate, in SSc patients (pts) with microstomia due to TMJ dysfunction, the efficacy of 2 rehabilitation protocol. <h3>Methods</h3> We enrolled 26 SSc pts (22 women, 4 men; age and disease duration: 59.08±10.31 and 13.65±5.71 years) with microstomia and TMJ dysfunction. Group 1 (13 pts) was treated by Protocol 1 (P1) (home exercises for mimic, masticatory and neck muscles; 20 minutes/day, 3 days/week) and group 2 (13 pts) was treated by Protocol 2 (exercises plus face and neck,connective tissue massage, Kabat technique for mimic muscles, manual techniques -intra- and extra-oral manipulation of TMJ, stretching and mobilization of cranio-cervical muscles-; 1 hour/week). Pts were evaluated at T0, at T1 (end of treatment; week 12) and at T2 (at 8 weeks of follow-up) by: Helkimo Index (Anamnestic -A-dysfunction -D- and occlusal-O- index), for TMJ dysfunction; mobility of cervical rachis (cm) and mouth (ROM) (mm); SSc face involvement (facial skin score; Mouth Handicap in SSc scale–MHISS-). <h3>Results</h3> At T1, both protocols improved Helkimo A index and Helkimo O Score, while only protocol 2 improved Helkimo D (p&lt;0.05).Mouth left lateralization and protrusion were improved by both protocols while mouth opening and right lateralization were increased only by P2 (p&lt;0.05). At T1, P1 improved cervical anterior flexion and left rotation (p&lt;0.05), with the latter result confirmed at T2 versus (vs) T0 (p&lt;0.01), P2 ameliorated cervical right lateralization, while both protocols improved cervical left lateralization, right rotation and extension (p&lt;0.05), with the latter result confirmed at T2 vs T0 for P1 and P2 (p&lt;0.05). Both protocols reduced facial skin score at T1 (p&lt;0.01), with the results confirmed at T2 vs T0 for both treatments (p=NS). P2 also improves at T1 vs T0 values of MHISS (p&lt;0.05). <h3>Conclusions</h3> In SSc patients, both protocols improve TMJ and cervical mobilization, TMJ disability, and skin score. with some of the results confirmed at follow-up. P2, also improving SSc face disability, seems to ameliorate more items than P1 and to be more efficacious than P1. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4505
Abstract 3438: Oncogenes-induced interferon-beta: modulation of tranformation phenotypes through interferon-ISG15 autocrine signaling
Authors: Yu-Chen Tsai, Sidney Pestka, Lu-Hai Wang, Loren W. Runnels, Leroy F. Liu
Journal: Cancer Research (2011)

Abstract ISG15 (interferon-stimulated gene 15), an ubiquitin-like protein (UBL), is a new tumor marker whose expression has been correlated with disease progression in bladder cancer and suggested to be prognostic for breast cancer. However, the molecular basis for, and the function of, ISG15 overexpression in tumors remain unclear. Here, we show that ISG15 overexpression in both breast cancer cells and oncogenic Ras-transformed mammary epithelial cells (MCF-10A) is due to elevated secretion of interferon-β. Moreover, interferon-β-ISG15 autocrine signaling in oncogenic Ras-transformed MCF-10A cells results in increased colony formation efficiency. Interestingly, gain of epithelial-mesenchymal transition (EMT) characteristics, including appearance of spindle-shaped cell morphology and EMT markers, as well as increased cell migration, in Ras-transformed MCF-10A cells is also dependent on interferon-β-ISG15 autocrine signaling. Our results demonstrate for the first time that tumor cell-secreted interferon-β may modulate tumor cell growth and migration through ISG15, suggesting potential cancer therapeutic approaches by antagonizing interferon autocrine signaling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3438. doi:10.1158/1538-7445.AM2011-3438
In-111 Pentetreotide Scintigraphy to Monitor Nonsecreting Neuroendocrine Tumors
Authors: P D Buffaz, J P Vuillez, O Chabre, C Cura, R Barnoud, D Pasquier, A Dupre, D Fagret
Journal: Clinical Nuclear Medicine (1999)

Nonsecreting neuroendocrine tumors pose problems because of the absence of hypersecretion symptoms. Such tumors are difficult to monitor, because recurrence can be detected only through morphologic evaluation, which lack sensitivity. A 66-year-old woman was evaluated by In-111 pentetreotide scintigraphy after the chance discovery of a nonsecreting neuroendocrine tumor. This revealed a single metastasis that could not be visualized by other imaging techniques, and the scintigraphic results were helpful for the surgical procedure. This clinical case illustrates the crucial role of pentetreotide scintigraphy in diagnosing neuroendocrine tumors and assessing their spread.
Lenalidomide in Myeloma — A High-Maintenance Friend
Authors: Ashraf Z. Badros
Journal: New England Journal of Medicine (2012)

With the introduction of high-dose therapy and new agents, outcomes of treatment have improved considerably for patients with myeloma.1 As therapy has become more effective, the goals of therapy have wavered between fixed-duration therapy aimed at eradication of the malignant clone and maintenance of remission.Previous trials of maintenance therapy were hindered by toxic effects and the failure of several agents (including glucocorticoids, interferon, and chemotherapy) to consistently improve progression-free survival and overall survival.2 Thalidomide consistently improved progression-free survival and, in some trials, overall survival, but it was poorly tolerated.3 In contrast, lenalidomide has a favorable toxicity profile, and its . . .
Endoscopic removal of the Padlock-G clip
Authors: D. von Renteln, M. Vassiliou, R. Rothstein
Journal: Endoscopy (2010)

In recent years various new endoscopic closure techniques and devices have been developed [1]. Research has mainly been driven by the need for a secure and reliable closure for natural orifice transluminal endoscopic surgery (NOTES) [2]. At present, the clinical applicability of NOTES remains unclear, but research in this area has already immeasurably enriched our endoscopic armamentarium with regards to endoscopic closure of perforations [1] [3] [4].
Coût de la prise en charge de l'hémorragie digestive par rupture des varices oesophagiennes chez les patients cirrhotiques à Fès au Maroc
Authors: M Ould Mohamed El Agheb, M Azouaoui, I Mellouki, M El Yousfi, DA Benajah, M El Abkari, N Aqodad, A Ibrahimi
Journal: Endoscopy (2012)

L'hémorragie digestive par rupture des varices oesophagiennes (VO) est une complication grave de l'HTP, elle représente la deuxième cause de l'hémorragie digestive haute, sa prise en charge est difficile et coûteuse. Le but de notre étude était d'estimer le coût de la prise en charge de l'hémorragie digestive par rupture des VO chez les patients cirrhotiques à Fès au Maroc.
A Patient with Migrating Polyarthralgias
Authors: Jonathan D. Casey, Anand Vaidya, Daniel H. Solomon, Thomas A. Gaziano
Journal: New England Journal of Medicine (2013)

A 28-year-old woman with no known medical problems presented to the emergency department with a 2-week history of joint pain and fatigue. The pain first developed in association with swelling of her right foot and ankle that made it difficult for her to stand or walk. The pain and swelling resolved spontaneously in several days, but she then noted pain in her knees and hips, as well as . . .
Mantle cell lymphoma of the colon
Authors: Mohammad Esmadi, Dina Ahmad, Deiter Duff, Hazem Hammad
Journal: Endoscopy (2014)

An 81-year-old man with a history of stage IV mantle cell lymphoma (MCL) diagnosed from a submental lymph node biopsy in 2006 was evaluated for new-onset melena and blood clots with bowel movements. He had been treated for his MCL with 6 cycles of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) in 2006, followed by 13 cycles of maintenance rituximab. In 2012, he was started on lenalidomide (Revlimid), but decided to stop after an exacerbation of his heart failure.
A Massive Cystic Dysplastic Kidney Shown on a DMSA Scan
Authors: KEVIN K. L. CHOONG
Journal: Clinical Nuclear Medicine (2000)

Standard renal imaging with Tc-99m DMSA is performed 3 to 4 hours after injection. The additional diagnostic value of early and delayed views in a neonate with a massive cystic mass is described. The additional views obviated misdiagnosis by clearly distinguishing a displaced urinary bladder from possible functioning renal tissue.
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Authors: Peter J. Barnes, Michael Karin
Journal: New England Journal of Medicine (1997)

In chronic inflammatory diseases, such as asthma, rheumatoid arthritis, inflammatory bowel disease, and psoriasis, several cytokines recruit activated immune and inflammatory cells to the site of lesions, thereby amplifying and perpetuating the inflammatory state.1 These activated cells produce many other mediators of inflammation.What causes these diseases is still a mystery, but the disease process results from an interplay of genetic and environmental factors. Genes, such as those for atopy in asthma and for HLA antigens in rheumatoid arthritis and inflammatory bowel disease, may determine a patient's susceptibility to the disease and the disease's severity, but environmental factors, often unknown, . . .
SP0172 What Can a Occupational Therapist Contribute
Authors: I. S. Masselink
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Occupational therapy is a client-centred health profession concerned with promoting health and well being through occupation. The primary goal of occupational therapy is to enable people to participate in the activities of everyday life. Occupational therapists achieve this outcome by working with people and communities to enhance their ability to engage in the occupations they want to, need to, or are expected to do, or by modifying the occupation or the environment to better support their occupational engagement. The occupational therapist involved in care of the individual with rheumatic disease assess and evaluates: - Activities of Daily Living and Assistive Devices - Hand Assessment - Joint Protection and Energy Conservation - Leisure - Psychological Wellbeing - Sexuality, Parenting and Family Relationships - Splinting - Employment This presentation will provide an overview of the contribution of the occupational therapist to treatment of the individual with rheumatic disease. <h3>Disclosure of Interest</h3> None Declared
Stat Bite: U.S. Cancer Incidence and Mortality by Race/Ethnicity, 1977-83
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1993)

Stat Bite : U.S. Cancer Incidence and Mortality by Race/Ethnicity, 1977–83 Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 5, 3 March 1993, Page 349, https://doi.org/10.1093/jnci/85.5.349 Published: 03 March 1993
Abstract 4980: Myeloid cells display immunosuppression activities during pregnancy, participating to the establishment of pre-metastatic niches.
Authors: Marie-Aude Le Bitoux, Sabine Waeber, Ivan Stamenkovic
Journal: Cancer Research (2013)

Abstract During pregnancy, major physiological changes occur that include inflammation and reduced immunity, conditions that are both implicated in promoting tumor growth. Tumors are indeed more aggressive during pregnancy and have greater metastatic proclivity. To gain insight into the mechanisms that may render pregnancy permissive for tumor growth, we addressed the biological and functional properties of myeloid-derived suppressor cells (MDSC), a heterogeneous population of hematopoietic cells of variable plasticity and immunoregulatory properties, during mouse and human gestation. Gene expression profiling of mouse MDSC has been shown to differ in pregnant and virgin mice, and the gene expression profile of pregnant animal-derived MDSC bears similarity to that observed in MDSC of tumor bearing mice. Common induced genes include Fibronectin1 and Olfactomedin4, which are known to be involved in extracellular matrix remodeling and tissue permissiveness to tumor cell implantation. In human pregnancy, CD33+ myeloid cells isolated from peripheral blood mononuclear cells (PBMC) are shown to be more strongly inhibitory of T cell proliferation in pregnant than in non-pregnant women. We also observed reduced natural killer cell numbers in the circulation of pregnant women, but which was not linked to a decrease in their cytotoxic activity, even after co-culture with CD33+ PBMC. Our observations suggest that mouse MDSC, as well as human CD33+ cell populations that arise during the physiological state of gestation, mimic tumor progression-associated MDSC and participate in the constitution of a permissive soil, often referred to as the pre-metastatic niche. Citation Format: Marie-Aude Le Bitoux, Sabine Waeber, Ivan Stamenkovic. Myeloid cells display immunosuppression activities during pregnancy, participating to the establishment of pre-metastatic niches. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4980. doi:10.1158/1538-7445.AM2013-4980
DUAL PLATELET REACTIVITY TESTING IN ACUTE CORONARY SYNDROME
Authors: Mark Y.Y. Chan, Leonardo Carvalho, Alan Fong, Chee Tang Chin, Sock Cheng Poh, Christopher Frampton, Chi-Hang Lee, Adrian Low, Huay-Cheem Tan, Richard Troughton, Bryan P. Yan, Siew-Pang Chan, Mark Richards
Journal: Journal of the American College of Cardiology (2016)
DOES PRE-EXISTING AORTIC REGURGITATION PROTECTS FROM DEATH IN PATIENTS WHO DEVELOP PARAVALVULAR LEAK AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION?
Authors: Andrea Colli, Stefano Salizzoni, Laura Besola, Dario Gregori, Marco Agrifoglio, Alaide Chieffo, Tommaso Regesta, Giuseppe Tarantini, Davide Gabbieri, Francesco Saia, Corrado Tamburino, Flavio Ribichini, Orazio Valsecchi, Bruno Loi, Alessandro Iadanza, Gennaro Santoro, Alessandro Minati, Gianluca Martinelli, Francesco Bedogni, Anna Petronio, Michele Dallago, Antonio Colombo, Augusto D’Onofrio, Gino Gerosa, Mauro Rinaldi
Journal: Journal of the American College of Cardiology (2015)